Translate
Translate this website into the following languages:



Close Tab
Donations
UC San Diego Health
menu iconMenu
search iconSearch

Immune System Molecule Promotes Tumor Resistance to Anti-Angiogenic Therapy

 

August 05, 2013  |  

A team of scientists, led by Napoleone Ferrara, MD, has shown for the first time that a signaling protein involved in inflammation also promotes tumor resistance to anti-angiogenic therapy.

The findings by Ferrara – professor of pathology at the University of California, San Diego School of Medicine and senior deputy director for basic science at the UC San Diego Moores Cancer Center – and colleagues at Genentech, a biotechnology firm based in South San Francisco, are published in the August 4 Advance Online Publication of the journal Nature Medicine.

Angiogenesis is a physiological process in which new blood vessels form from existing vessels. It is fundamental to early development and wound healing, but some cancer tumors exploit angiogenesis to promote blood vessel growth and fuel a tumor’s transition from a benign to a malignant state.

In the late 1980s, Ferrara led efforts to identify a key gene (VEGF) involved in angiogenesis and subsequent development of the first drugs to block VEGF-mediated growth in a variety of cancers, among them lung, kidney, brain and colorectal. Researchers discovered, however, that similar to other therapies, VEGF-targeting drugs may lose effectiveness as tumors develop resistance, allowing cancers to recur.

The latest research highlights the role of interleukin-17 or IL-17, one of a family of signaling molecules called cytokines that are involved in the body’s immune response. Ferrara and colleagues discovered that IL-17 signaling in tumor-infiltrating T cells, part of the body’s adaptive immune response, encourages resistance to the VEGF-blockade in mouse models.

“Our work has the potential to have major translational and therapeutic relevance,” said Ferrara.  “By inhibiting the effects of IL-17 with monoclonal antibodies or other blockers, we can potentially improve the clinical efficacy of VEGF-targeting drugs.”

Co-authors include Alicia S. Chung, Xiumin Wu, Guanglei Zhuang, Hai Ngu, Ian Kasman, Jianhuan Zhang, Jean-Michel Vernes, Zhaoshi Jiang, Y. Gloria Meng, Franklin V. Peale and Wenjun Ouyang, all at Genentech, Inc.

# # #

Media Contact: Scott LaFee, 619-543-6163, slafee@ucsd.edu


Related Specialties

Cancer



Media Contact

Share This Article


Related News

8/31/2016
Roger Tsien, PhD, co-winner of the 2008 Nobel Prize in chemistry and professor of pharmacology, chemistry and biochemistry at University of California San Diego School of Medicine for 27 years, died A ...
7/21/2016
In an effort to expand the number of cancer gene mutations that can be specifically targeted with personalized therapies, researchers at University of California San Diego School of Medicine and Moore ...
4/18/2016
Cancer is rarely the result of a single mutation in a single gene. Rather, tumors arise from the complex interplay between any number of mutually exclusive abnormal changes in the genome, the combinat ...
2/23/2016
Cancer immunology is based upon boosting the body’s own immune system to vanquish malignancies. It is among the fastest growing areas of oncology research. Researchers at UC San Diego Moores Cancer Ce ...



Follow Us

Our bimonthly newsletter delivers healthy lifestyle tips, patient stories and research discovery news. Subscribe: